Arcellx, Inc.
ACLX
Kedudukan dalam Saham
#2780
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Harga Saham
$115.07
Disegerakkan terakhir: 2026-05-15
Modal Pasaran
$6.73B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
32.61%
Negara
US
Perdagangan Arcellx, Inc. (ACLX)
Kategori
Healthcare
Bilangan saham terbitan bagi Arcellx, Inc. (ACLX)
Bilangan saham terbitan setakat December 2025: 56.31M
Menurut laporan kewangan terkini dan harga saham Arcellx, Inc., bilangan saham terbitan semasa ialah 56.31M. Pada akhir December 2023, syarikat mempunyai 48.06M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Arcellx, Inc. (ACLX) dari 2018 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 56.31M | 5.11% |
| 2024 | 53.57M | 11.45% |
| 2023 | 48.06M | 8.97% |
| 2022 | 44.11M | 31.49% |
| 2021 | 33.54M | 54.04% |
| 2020 | 21.78M | -37.39% |
| 2019 | 34.78M | 20,905.45% |
| 2018 | 165.58K | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 350.93% |
US
|
|
| 396.00M | 603.31% |
US
|
|
| 478.91M | 750.56% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 10.44% |
NL
|
